Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5033949 | 0.88 | KMT2A (0.44) | KMT2AMEN1GAAMAPTPOLB | |
| SCHEMBL5041301 | 0.86 | KMT2A (0.43) | KMT2AMEN1GAAMAPTPOLB | |
| SCHEMBL5042457 | 0.84 | KMT2A (0.44) | KMT2AMEN1GAAMAPTALDH1A1 | |
| SCHEMBL6021965 | 0.76 | KMT2A (0.43) | KMT2AMEN1GAAMAPTPOLB | |
| SCHEMBL5047748 | 0.68 | POLB (0.40) | KMT2AMEN1GAAMAPTPOLB | |
| SCHEMBL29668460 | 0.67 | KMT2A (0.66) | KMT2AMEN1GAAPOLBALDH1A1 | |
| SCHEMBL5033945 | 0.65 | TSHR (0.41) | KMT2AMEN1GAAMAPTPOLB | |
| SCHEMBL5038287 | 0.65 | GABRP (0.41) | KMT2AMEN1GAAMAPTALDH1A1 | |
| SCHEMBL6021711 | 0.64 | KMT2A (0.43) | KMT2AMEN1GAAMAPTPOLB | |
| SCHEMBL29191087 | 0.64 | MAPK14 (0.57) | KMT2AGAAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660487-B1 | PYRROLE COMPOSITIONS USEFUL AS INHIBITORS OF C-MET | VERTEX PHARMA (US) | 2008-03-19 | — | — | EP | disclosed |
| US-7314885-B2 | Pyrrole compounds useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-01 | — | — | US | disclosed |
| US-20060173055-A1 | (4-(4-(2,3-difluorophenyl)-4H-1,2,4-triazol-3-yl)-1H-pyrrol-2-yl)(2H-pyrrol-1(5H)-yl)methanone; anticarcinogenic, antiproliferative and antimetastasis agent; inhibitors of c-Met protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| US-20050101650-A1 | Pyrrole compositions useful as inhibitors of c-Met | VERTEX PHARMACEUTICALS INCORPORATED | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101650-A1 | Pyrrole compositions useful as inhibitors of c-Met | MET, PRKCH, DMPK | KMT2A 1635/4885MEN1 493/4885GAA 2737/4885 |
| US-20060173055-A1 | (4-(4-(2,3-difluorophenyl)-4H-1,2,4-triazol-3-yl)-1H-pyrrol-2-yl)(2H-pyrrol-1(5H)-yl)methanone; anticarcinogenic, antiproliferative and antimetastasis agent; inhibitors of c-Met protein kinase | MET, DMPK, CDK4 | KMT2A 1414/4885MEN1 494/4885GAA 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.